Long-term Monitoring of Growth and Development of Pediatric Patients Previously Treated With Everolimus
- First Posted Date
- 2015-01-14
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 15
- Registration Number
- NCT02338609
- Locations
- 🇺🇸
Cinn Children Hosp Medical Center SC, Cincinnati, Ohio, United States
🇷🇺Novartis Investigative Site, Moscow, Russian Federation
🇺🇸University Of California LA SC, Los Angeles, California, United States
A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges
- First Posted Date
- 2015-01-13
- Last Posted Date
- 2020-04-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 156
- Registration Number
- NCT02336451
- Locations
- 🇺🇸
The Ohio State University Comprehensive Cancer Center Ohio State University, Columbus, Ohio, United States
🇺🇸USC Kenneth Norris Comprehensive Cancer Center SC-3, Los Angeles, California, United States
🇺🇸Dana Farber Cancer Institute SC-12, Boston, Massachusetts, United States
Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma
- First Posted Date
- 2015-01-13
- Last Posted Date
- 2017-08-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 10
- Registration Number
- NCT02336425
- Locations
- 🇸🇰
Novartis Investigative Site, Zvolen, Slovakia
Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.
- First Posted Date
- 2015-01-12
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 177
- Registration Number
- NCT02335944
- Locations
- 🇨🇳
Novartis Investigative Site, Taipei, Taiwan ROC, Taiwan
🇺🇸Massachusetts General Hospital Mass General, Boston, Massachusetts, United States
PROFILE - Evaluation of QoL and PRO Outcomes in Patients Taking Fingolimod
- Conditions
- Relapsing Remitting Multiple Sclerosis
- First Posted Date
- 2015-01-12
- Last Posted Date
- 2019-04-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 114
- Registration Number
- NCT02335892
- Locations
- 🇬🇧
Novartis Investigative Site, Nottingham, United Kingdom
A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies
- Conditions
- Hereditary Periodic FeversSystemic Juvenile Idiopathic Arthritis
- Interventions
- First Posted Date
- 2015-01-08
- Last Posted Date
- 2020-05-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT02334748
- Locations
- 🇫🇷
Novartis Investigative Site, Paris, France
First-in-human Study to Assess the Safety and Pharmacokinetics of LML134 in Healthy Volunteers
- First Posted Date
- 2015-01-08
- Last Posted Date
- 2016-10-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 133
- Registration Number
- NCT02334449
- Locations
- 🇩🇪
Novartis Investigative Site, Berlin, Germany
Dose Range Finding Study of Bimagrumab in Sarcopenia
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 217
- Registration Number
- NCT02333331
- Locations
- 🇨🇳
Novartis Investigative Site, Taipei, Taiwan
A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
- Conditions
- Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
- Interventions
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 88
- Registration Number
- NCT02333370
- Locations
- 🇸🇬
Novartis Investigative Site, Singapore, Singapore
The Efficacy Study of Aclasta on Prosthetic Fixation in Postmenopausal Women After THA
- Conditions
- Prosthetic Fixation After Cementless Total Hip Arthroplasty
- Interventions
- Drug: Zoledronic acid 5mg
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2019-09-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT02333344
- Locations
- 🇨🇳
Novartis Investigative Site, Shanghai, Shanghai, China